#550: Evolving Artificial Intelligence Regulatory Landscape in Drug Development Across US and EU

Tuesday, June 16, 2026 4:15 PM to 5:15 PM · 1 hr. (America/New_York)
113 AB
03: Data-Tech-AI08: RegPolicy-Strategy-GlobalCollaboration

Information

This session examines evolving US and EU regulatory approaches to AI in drug development and explores how policy expectations are translated into real world GxP implementation. Attendees will gain insight into regulatory convergence, operational challenges, and good practices for compliant AI adoption.
CE
ACPECMERN
Session Level
Intermediate
Featured Topics
Artificial Intelligence
Learning Objectives
Compare and contrast US and EU regulatory frameworks governing AI use across the drug development lifecycle; Assess how regulatory expectations and emerging convergence efforts translate into practical implementation challenges; Identify good practices for operationalizing AI within GxP quality systems while maintaining compliance and innovation.

Registered attendees

AK
Aarti Kolluri
Senior Director - Clinical InnovationEli Lilly
AT
Abla Tannous
Principal Medical WriterKowa Research Institute
AC
Adam Clarke
Innovation ManagerBristol Myers Squibb